

Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 - 8 - 12 pm Eastern

Program Chair - Kathleen Moore, MD
Co-Chair - Paolo Tarantino, MD

Program Description

The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with ADC. Expert led discussions will provide evidence-based perspectives regarding important clinically relevant topics in drug selection, biomarkers, sequencing, and toxicity management. We will also review the future landscape of care and current as well as upcoming clinical trials. This timely and clinically relevant session aims to equip attendees with actionable knowledge that can be immediately applied in oncology practice.

Interactive case vignettes will offer practical guidance on patient selection, therapeutic strategies, and the management of adverse effects associated with ADCs. Additionally, ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of current ADC and novel future therapies will be explored.

Learning Objectives

Following this activity, participants will be better able to:

- **Explain** the development and mechanism of action of antibody-drug conjugates (ADCs) and identify mechanisms of resistance.
- **Discuss** the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
- **Recognize** and **Manage** adverse events associated with ADC therapy.

Target Audience

This symposium is intended for a broad oncology-focused audience, including members and non-members. Participants may include physicians, research staff, early-career investigators, clinical research associates, basic scientists, medical physicists, clinical trial nurses, patient advocates, and other healthcare professionals involved in cancer treatment and research.

[See presentation agenda on next page](#)

Summer 2025 Symposium

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 – NRG Oncology Semiannual Meeting - Washington, DC

Presentation Agenda

Program Chair: Kathleen Moore, MD / Co-Chair Paolo Tarantino, MD

Presentation Agenda		
Time	Topic/Title	Speaker/Moderator
6:30 am	Full Breakfast Buffet	
8:00 am	Welcome/Opening Remarks	Kathleen Moore, MD
8:05-9:35am	Session 1 <i>“Selection and ADCs in Gynecologic, Breast, Lung, GU and GI Cancers”</i>	Moderators: Ian Krop, MD
8:05 – 8:20	How do ADCs actually work? Magic Bullets or Just Fancy Chemotherapy?	Patricia LoRusso, DO, PhD
8:20 – 8:35	ADCs in Breast Cancer	Ian Krop, MD
8:35 – 8:50	Expanding ADCs in Lung Cancer	Biagio Ricciuti, MD
8:50 – 9:05	Evolution of ADCs in GI Oncology	Michael Cecchini, MD
9:05 – 9:20	Evolution of ADCs in GU Oncology	Shilpa Gupta, MD
9:20 - 9:35 am	Panel Discussion with Q/A	ALL
9:35 – 10:50 am	Session 2: <i>“Selection, Sequencing and Mechanism of Resistance- Patient Centric Development of ADCs”</i>	Moderator: Paolo Tarantino, MD
9:35 – 9:55	ADC Landscape in Gynecologic Cancers	Ramez Eskander, MD
9:55 - 10:15	Mechanisms of Resistance and Impact on ADC Sequencing	Paolo Tarantino, MD
10:15 – 10:35	ADC Toxicity: A Reality Check from Patients Living It	Julia Maues
10:35 – 10:50	Panel Discussion with Q/A	ALL
10:50 – 11:00	Coffee Break	
11:00 – 12:05 pm	Session 3: <i>“Future Developments, Optimization, and Safety”</i>	Moderator: Joyce Liu, MD –
11:00 – 11:20	New Frontiers of ADCs: ISACs, DACs, bispecific ADCs and beyond	Abdul Rafel Raqash, MD
11:20 – 11:40	Boosting the Activity of ADCs with Combinations	Leif W. Ellisen, MD, PHD
11:40 - 12:00	Regimen Optimization and Regulatory Considerations in ADC Development	Lauren Price, PharmD
12:00 – 12:10 pm	Panel Discussion with Q/A	ALL
12:10 pm	Closing Remarks	Kathleen Moore, MD and Paolo Tarantino, MD